Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Raloxifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 20/20 | 1.00 |
| ▸ | ESR2 known ✓ | Q92731 | 19/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | HLA-A | P04439 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | UBE2N | P61088 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | PLD2 | O14939 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Raloxifene SCHEMBL1665291 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL12485521 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL9201404 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL19077 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL7631648 | 0.99 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL975023 | 0.99 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL3162158 | 0.99 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Ly-117018 SCHEMBL7080240 | 0.99 | ESR1 (0.98) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL6144 | 0.99 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA | |
| Raloxifene SCHEMBL9145135 | 0.99 | ESR1 (1.00) | ESR1ESR2MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 762 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037385-B2 | Anti-polyubiquitin antibodies and methods of use | GENENTECH, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12030926-B2 | Production of heteromultimeric proteins using mammalian cells | GENENTECH, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240200146-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | GENENTECH INC (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240190967-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER | GENENTECH INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240175088-A1 | Methods and Systems for Analyzing Nucleic Acid Molecules | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-05-30 | — | — | US | disclosed |
| US-20240158513-A1 | FC Variants and Methods for Their Production | GENENTECH, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-11965215-B2 | Methods and systems for analyzing nucleic acid molecules | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-04-23 | — | — | US | disclosed |
| US-20240105281-A1 | Methods and Systems for Analyzing Nucleic Acid Molecules | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-03-28 | — | — | US | disclosed |
| EP-4334476-A1 | METHODS AND SYSTEMS FOR ANALYZING NUCLEIC ACID MOLECULES | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240067991-A1 | SYSTEMS AND METHODS FOR REGULATING GENE EXPRESSION OR ACTIVITY | FUNDAÇÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD FOUNDATION (PT) | 2024-02-29 | — | — | US | disclosed |
| US-20060057148-A1 | Compositions and methods for treatment of non-hodgkin's lymphoma | GENENTECH, INC. | 2006-03-16 | — | — | US | disclosed |
| WO-2006014335-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF NON-HODGKIN’S LYMPHOMA | GENENTECH, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006015371-A2 | HUMANIZED ANTI-CMET ANTAGONISTS | GENENTECH, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20050272120-A1 | Compositions and methods for the diagnosis and treatment of tumor | GENENTECH, INC. (US) | 2005-12-08 | — | — | US | disclosed |
| US-20050170368-A1 | Compositions and methods for the diagnosis and treatment of tumor | GENENTECH, INC. (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050106667-A1 | Variant complementary determining regions for use in identifying antigen binding polypeptides; mimetics; direceted protein evolution | GENENTECH, INC | 2005-05-19 | — | — | US | disclosed |
| US-20050090514-A1 | Trp-p8 active compounds and therapeutic treatment methods | GENENTECH, INC. | 2005-04-28 | — | — | US | disclosed |
| WO-2005012531-A2 | ANTIBODY CDR POLYPEPTIDE SEQUENCES WITH RESTRICTED DIVERSITY | GENENTECH, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005002582-A2 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS | GENENTECH, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005003154-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | GENENTECH, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090514-A1 | Trp-p8 active compounds and therapeutic treatment methods | TSG101, TP53, BAX | ESR1 2393/4885ESR2 2809/4885MEN1 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.